Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zenocutuzumab by Merus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Pre-Registration drugs...
Zenocutuzumab by Merus for Metastatic Breast Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Zenocutuzumab by Merus for Non-Small Cell Lung Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData, Pre-Registration...
Risk adjusted net present value: What is the current valuation of Merus's Zenocutuzumab?
Zenocutuzumab is a monoclonal antibody commercialized by Merus, with a leading Pre-Registration program in Non-Small Cell Lung Cancer. According to...